Study on the effect of Shallaki (Boswellia serrata Roxb.) on the Pharmacokinetics of Pioglitazone in Rat Plasma
Jayasree Biju, Dr. Rajesh Sharma and E Manivannan
The study is designed to test the pharmacokinetic interaction of pioglitazone with shallaki in rats. Group I received pioglitazone 10mg/kg p.o and group II received 415mg/kg of extract equivalent to 250mg/kg of boswellic acid p.o and given 30min. before the administration of pioglitazone once daily for 8 days. Blood samples were collected on day 0 and day 8 of treatment. Pioglitazone was extracted and plasma concentration estimated using HPLC. With single dose treatment Cmax (p<0.001) and AUC0-24hr (p<0.01) of pioglitazone were significantly increased whereas it had no significant effect on the Tmax, Kel and t1/2 (p>0.05). But with one week repeated administration, Cmax (p<0.001), Tmax (p<0.001), AUC0-24hr (p<0.001) and t1/2 (p<0.001) were significantly increased and Kel (p<0.001) is significantly decreased. The study reveals that shallaki increases the bioavailability of pioglitazone when given concurrently, which could be due to increased absorption or decreased metabolism and elimination or a combination of both.
How to cite this article:
Jayasree Biju, Dr. Rajesh Sharma, E Manivannan. Study on the effect of Shallaki (Boswellia serrata Roxb.) on the Pharmacokinetics of Pioglitazone in Rat Plasma. Pharma Innovation 2017;6(7):374-376.